Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/nrc.2018.6

http://scihub22266oqcxt.onion/10.1038/nrc.2018.6
suck pdf from google scholar
C5912991!5912991 !29449659
unlimited free pdf from europmc29449659
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29449659 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid29449659
      Nat+Rev+Cancer 2018 ; 18 (5 ): 313-322
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Using immunotherapy to boost the abscopal effect #MMPMID29449659
  • Ngwa W ; Irabor OC ; Schoenfeld JD ; Hesser J ; Demaria S ; Formenti SC
  • Nat Rev Cancer 2018[May]; 18 (5 ): 313-322 PMID29449659 show ga
  • More than 60 years ago, the effect whereby radiotherapy at one site may lead to regression of metastatic cancer at distant sites that are not irradiated was described and called the abscopal effect (from 'ab scopus', that is, away from the target). The abscopal effect has been connected to mechanisms involving the immune system. However, the effect is rare because at the time of treatment, established immune-tolerance mechanisms may hamper the development of sufficiently robust abscopal responses. Today, the growing consensus is that combining radiotherapy with immunotherapy provides an opportunity to boost abscopal response rates, extending the use of radiotherapy to treatment of both local and metastatic disease. In this Opinion article, we review evidence for this growing consensus and highlight emerging limitations to boosting the abscopal effect using immunotherapy. This is followed by a perspective on current and potential cross-disciplinary approaches, including the use of smart materials to address these limitations.
  • |Animals [MESH]
  • |Biomarkers, Tumor/*analysis [MESH]
  • |Combined Modality Therapy [MESH]
  • |Dose-Response Relationship, Immunologic [MESH]
  • |Dose-Response Relationship, Radiation [MESH]
  • |Drug Carriers/*administration & dosage [MESH]
  • |Drug Delivery Systems [MESH]
  • |Humans [MESH]
  • |Immunosuppression Therapy [MESH]
  • |Immunotherapy/adverse effects/*methods [MESH]
  • |Nanoparticles/administration & dosage [MESH]
  • |Neoplasms/*therapy [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box